Three TIGIT players look to surprise in 2023

After Gilead/Arcus’s Arc-7 study of domvanalimab yielded its first results last month, 2023 promises more catalysts for this and two other anti-Tigit projects. However, there is little to suggest that this drug class’s disappointing track record is about to change.

Domvanalimab itself will yield a more mature data cut from Arc-7 at Asco, but it is the first look at overall survival from the Skyscraper-01 study of Roche’s tiragolumab, due in the current quarter, that has investors’ immediate attention. And Merck & Co will soon present the first pivotal data for vibostolimab, an asset about which little has been disclosed.